LURASIDONE HYDROCHLORIDE

Post-LOE

lurasidone hydrochloride

Jubilant Therapeutics

ANDAORALTABLET

Approved

Jan 2019

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

LURASIDONE HYDROCHLORIDE (lurasidone hydrochloride) by Jubilant Therapeutics is unclear. Approved for schizophrenia, depression, schizophrenia. First approved in 2019.

Drug data last refreshed 20h ago

Mechanism of Action

unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D 2 and serotonin Type 2 (5HT 2A ) receptor antagonism.

Indications (2)

schizophrenia depression

Worked on LURASIDONE HYDROCHLORIDE at Jubilant Therapeutics? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.